CLDN1

Across TCGA pan-cancer cohorts, CLDN1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLDN1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CLDN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLDN1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where CLDN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	IV	0.532	0.906	.018	7	view →
CCRCC	DFS	Quartile	All	0.395	0.893	.032	7	view →
PDAC	OS	Tertile	IV	0.934	0.472	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLDN1–HNSC (DFS)

Open the HNSC breakdown →